Form D/A — Aviceda Therapeutics, Inc.
0001824762-25-000001 · filed Jan 13, 2025
Figures are issuer-reported and describe stored filings. Data coverage and methodology.
Check this disclosure on SEC EDGAR · More Biotechnology filings
Offering
- Industry
- Biotechnology
- Exemptions
- Rule 506(b)
- Reported offering amount
- $207,499,882
- Reported amount sold
- $74,999,940
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- Aviceda Therapeutics, Inc.
- CIK
- 1824762
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- —
- Address
- ONE BROADWAY, 14TH FLOOR
CAMBRIDGE, Massachusetts 02142 - Phone
- 617-332-0741
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Mohamed Genead · Executive OfficerCambridge, Massachusetts Find on LinkedIn ↗
-
Michael Tolentino · Executive OfficerCambridge, Massachusetts Find on LinkedIn ↗
-
Nancy Thomason · DirectorCambridge, Massachusetts Find on LinkedIn ↗
-
Christoph Adams · DirectorCambridge, Massachusetts Find on LinkedIn ↗
-
David Guyer · DirectorCambridge, Massachusetts Find on LinkedIn ↗
-
Jay Woods · DirectorCambridge, Massachusetts Find on LinkedIn ↗
-
Erin Lavelle · DirectorCambridge, Massachusetts Find on LinkedIn ↗
-
David Callanan · Executive OfficerCambridge, Massachusetts Find on LinkedIn ↗
-
Tarek Hassan · Executive OfficerCambridge, Massachusetts Find on LinkedIn ↗
-
Derek Kunimoto · Executive OfficerCambridge, Massachusetts Find on LinkedIn ↗
View the original filing on SEC EDGAR ↗